| 2025-10-29 |
详情>>
股本变动：
变动后总股本77115.04万股
|
| 2025-10-21 |
详情>>
内部人交易：
DUGGAN ROBERT W等共交易3笔
|
| 2025-10-20 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.16美元,归母净利润-8.6亿美元,同比去年增长-437.38%
|
| 2025-10-20 |
财报披露：
美东时间 2025-10-20 盘前发布财报
|
| 2025-08-11 |
详情>>
业绩披露：
2025年中报每股收益-0.85美元,归母净利润-6.29亿美元,同比去年增长-505.27%
|
| 2025-07-03 |
复牌提示：
2025-07-03 10:19:29 停牌，复牌日期 2025-07-03 10:24:29
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益-0.09美元,归母净利润-6291.3万美元,同比去年增长-44.72%
|
| 2025-04-29 |
股东大会：
将于2025-06-12召开股东大会
会议内容 ▼▲
- 1.To elect nine directors from the nominees named in the accompanying Proxy Statement to hold office until our 2026 annual meeting of stockholders and until their successors are duly elected and qualified, subject to earlier resignation or removal;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To approve, by a non-binding advisory vote, the compensation of our named executive officers (“NEOs”);
4.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2025-02-24 |
详情>>
业绩披露：
2024年年报每股收益-0.31美元,归母净利润-2.21亿美元,同比去年增长64.01%
|
| 2024-10-30 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.22美元,归母净利润-1.6亿美元,同比去年增长72.32%
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益-0.15美元,归母净利润-1.04亿美元,同比去年增长81.36%
|
| 2024-05-01 |
详情>>
业绩披露：
2024年一季报每股收益-0.06美元,归母净利润-4347.3万美元,同比去年增长91.98%
|
| 2024-04-25 |
股东大会：
将于2024-06-14召开股东大会
会议内容 ▼▲
- 1.To elect nine directors from the nominees named in the accompanying Proxy Statement to hold office until our 2025 annual meeting of stockholders and until their successors are duly elected and qualified, subject to earlier resignation or removal;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To approve, by a non-binding advisory vote, the compensation of our named executive officers;
4.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2024-02-20 |
详情>>
业绩披露：
2023年年报每股收益-0.99美元,归母净利润-6.15亿美元,同比去年增长-680.54%
|
| 2023-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.98美元,归母净利润-5.78亿美元,同比去年增长-871.17%
|
| 2023-09-19 |
股东大会：
将于2023-10-12召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan (the “Plan”), to increase the number of shares of the Company’s common stock issuable under the Plan by 70,000,000 shares.
2.To transact any other business as may properly come before the Special Meeting or any adjournments or postponements thereof.
|
| 2023-08-09 |
详情>>
业绩披露：
2023年中报每股收益-1.03美元,归母净利润-5.57亿美元,同比去年增长-1359.58%
|
| 2023-04-21 |
股东大会：
将于2023-05-23召开股东大会
会议内容 ▼▲
- 1.To elect eight directors from the nominees named in the accompanying proxy statement to hold office until our 2024 annual meeting of stockholders and until their successors are duly elected and qualified, subject to earlier resignation or removal;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To approve, by a non-binding advisory vote, the compensation of our named executive officers;
4.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2022-12-13 |
股东大会：
将于2023-01-06召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock by 650,000,000 (from 350,000,000 to 1,000,000,000), with the final decision of whether to proceed with the amendment to be determined by our board of directors, in its discretion, following stockholder approval (if obtained), but no later than January 6, 2024.
2.To approve an amendment to our Restated Certificate of Incorporation to effect a reverse stock split of all of the outstanding shares of our Common Stock at a ratio in the range of 1-for-5 to 1-for-10, with the final decision of whether to proceed with the reverse stock split and the exact ratio and timing of the reverse split to be determined by our board of directors , in its discretion, following stockholder approval (if obtained), but no later than January 6, 2024.
|
| 2022-07-06 |
股东大会：
将于2022-07-27召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock by 100,000,000 (from 250,000,000 to 350,000,000).
2.To approve an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan (the “Plan”), to increase the number of shares of the Company’s common stock issuable under the Plan by 8,000,000 shares.
3.To transact any other business as may properly come before the Special Meeting or any adjournments or postponements thereof.
|
| 2022-04-29 |
股东大会：
将于2022-06-15召开股东大会
会议内容 ▼▲
- 1.To elect six directors from the nominees named in the accompanying proxy statement to hold office until our 2023 annual meeting of stockholders and until their successors are duly elected and qualified, subject to earlier resignation or removal;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To approve, by a non-binding advisory vote, the compensation of our named executive officers;
4.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-29 |
股东大会：
将于2021-06-16召开股东大会
会议内容 ▼▲
- 1.To elect five directors from the nominees named in the accompanying proxy statement to hold office until our 2022 annual meeting of stockholders and until their successors are duly elected and qualified, subject to earlier resignation or removal;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To approve, by a non-binding advisory vote, the compensation of our named executive officers;
4.To consider, by a non-binding advisory vote, the frequency of the advisory vote on the compensation of our named executive officers;
5.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2019-01-04 |
股东大会：
将于2019-01-04召开股东大会
会议内容 ▼▲
- 1.To authorise the Directors to allot and issue new ordinary shares
2.To dis-apply pre-emption rights
3.To approve the waiver of Rule 9 of the Takeover Code
|
| 2017-04-25 |
股东大会：
将于2017-07-18召开股东大会
|
| 2016-06-17 |
股东大会：
将于2016-07-18召开股东大会
|
| 2015-06-01 |
股东大会：
将于2015-07-14召开股东大会
|